Importance of nondopaminergic features in evaluating disease severity of Parkinson disease

Neurology

Volumn 82, Issue 5, 2014, Pages 412-418

  Van Der Heeden, Jorine F ^a   Marinus, Johan ^a   Martinez Martin, Pablo ^b   Van Hilten, Jacobus J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ABNORMAL POSTURE; ADULT; AGE DISTRIBUTION; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL FEATURE; COGNITIVE DEFECT; COHORT ANALYSIS; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GAIT DISORDER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS;

ADOLESCENT; AGED; CHILD; COHORT STUDIES; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PRINCIPAL COMPONENT ANALYSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84895731990     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000087     Document Type: Article

References (40)

1. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012;27:8-30.
2. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010; 16:653-661.
3. van Rooden SM, Visser M, Verbaan D, Marinus J, van Hilten JJ. Patterns of motor and non-motor features in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:846-850.
4. van Rooden SM, Colas F, Martinez-Martin P, et al. Clinical subtypes of Parkinson's disease. Mov Disord 2011;26: 51-58.
5. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
6. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007;69:333-341.
7. ELEP Group. A longitudinal study of patients with Parkinson's disease (ELEP): aims and methodology. Rev Neurol 2006;42:360-365.
8. Rodriguez-Oroz MC, Moro E, Krack P. Long-term outcomes of surgical therapies for Parkinson's disease. Mov Disord 2012;27:1718-1728.
9. Marinus J, Visser M, Stiggelbout AM, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry 2004;75:388-395.
10. Visser M, Verbaan D, van Rooden SM, Stiggelbout AM, Marinus J, van Hilten JJ. Assessment of psychiatric complications in Parkinson's disease: the SCOPA-PC. Mov Disord 2007;22:2221-2228.
11. Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM. Assessment of sleep and sleepiness in Parkinson disease. Sleep 2003;26:1049-1054.
12. Visser M, Marinus J, Stiggelbout AM, van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004;19:1306-1312.
13. Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson's disease. Neurology 2003;61:1222-1228.
14. Beck AT, Ward CH, Mendelson M, Mock J, Erbauch J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
15. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-370.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
17. Swinscow TDV, Campbell MJ. Statistics at Square One. London: BMJ Books; 2002.
18. Fayers PM, Machin D. Factor analysis. In: Staquet MJ, Hays RD, Fayers PM, editors. Quality of Life Assessment in Clinical Trials: Methods and Practice. New York: Oxford University Press; 1998:191-223.
19. Pallant J. SPSS Survival Manual, 2nd ed. Maidenhead, UK: Open University Press; 2005.
20. Field A. Discovering Statistics Using SPSS, 3rd ed. London: SAGE Publications Ltd.; 2009.
21. Aaronson N, Alonso J, Burnam A, et al. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002;11:193-205.
22. Clark LA, Watson D. Constructing validity: basic issues in objective scale development. Psychol Assess 1995;7:309-319.
23. Nunnally JC, Bernstein IH. Psychometric Theory, 3rd ed. New York: McGraw-Hill; 1994.
24. Factor SA, Steenland NK, Higgins DS, et al. Diseaserelated and genetic correlates of psychotic symptoms in Parkinson's disease. Mov Disord 2011;26:2190-2195.
25. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-745.
26. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson disease. Arch Neurol 1997;54:625-630.
27. Lord S, Galna B, Coleman S, Burn D, Rochester L. Mild depressive symptoms are associated with gait impairment in early Parkinson's disease. Mov Disord 2013;28:634-639.
28. Yogev G, Giladi N, Peretz C, Springer S, Simon ES, Hausdorff JM. Dual tasking, gait rhythmicity, and Parkinson's disease: which aspects of gait are attention demanding? Eur J Neurosci 2005;22:1248-1256.
29. Erro R, Picillo M, Vitale C, et al. Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 2013;84:14-17.
30. Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013;80:276-281.
31. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Subjective complaints precede Parkinson disease: the Rotterdam study. Arch Neurol 2006;63:362-365.
32. Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012;27:617-626.
33. Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2008;64:485-491.
34. Calabresi P, Mercuri NB, Di Filippo M. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. Brain 2009;132:285-287.
35. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010;67:715-725.
36. Schulz-Schaeffer WJ. The synaptic pathology of alphasynuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010;120:131-143.
37. Beach TG, Adler CH, Lue L, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009;117: 613-634.
38. Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009;8:1158-1171.
39. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
40. Levy G. The relationship of Parkinson disease with aging. Arch Neurol 2007;64:1242-1246.